Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Ava3.6

Avanafil (Stendra) – Forschung

Überwiegend Mechanismus / Beobachtung

7 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Avanafil (Stendra) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus gemischt-qualitativen Meta-Analysen und randomisierten Studien, veröffentlicht 2012–2025.

Basierend auf 7 Studien · 1 Meta-Analyse · 2 RCTs

Konfidenz

Mittlere Konfidenz

Nach Outcome

Erectile functionEvidenz aus Phase-3-RCTs und Metaanalysen für eine klinisch bedeutsame Verbesserung der erektilen Funktion gegenüber Placebo, auch bei Männern mit Diabetes; häufig innerhalb von ~15-30 Minuten wirksam · ~15-30 Minuten (bei Bedarf)
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung4 Studien
Cardiovascular & vascular
Zu wenige bewertete Studien2 Studien

Stetige Forschung

1 Studie in den letzten 5 Jahren · Neueste Meta-Analyse: 2014

201220182025

1Systematische Übersicht2025

However, there are limitations to the evidence that should be considered.

· Unknown Journal (2025)

What did we find? • We identified 3 relevant clinical studies.
What does this mean? • Initial combination therapy with 2 oral medications, an ERA and a PDE5 inhibitor, may provide better treatment outcomes in patients with PAH compared to monotherapy.
However, there are limitations to the evidence that should be considered.

2RCT2012

Avanafil significantly improved erectile function and was well tolerated across doses in men with erectile dysfunction.

Goldstein, McCullough, Jones, Hellstrom, Bowden, Didonato, Trask, Day · The Journal of Sexual Medicine (2012)

REVIVE: 12-week phase-3 double-blind, placebo-controlled RCT of on-demand avanafil (50, 100, 200 mg) in men with erectile dysfunction
Significant improvement on the IIEF erectile-function domain and per-attempt success versus placebo
Onset was rapid and the drug was well tolerated; common effects were headache, flushing, and nasal congestion

Quelle ansehen

3RCT2012

Avanafil significantly improved erectile function in men with diabetes mellitus and was generally well tolerated.

Goldstein, Jones, Belkoff, Karlin, Bowden, Peterson, Trask, Day · Mayo Clinic Proceedings (2012)

REVIVE-Diabetes: 12-week multicenter, randomized, double-blind RCT of avanafil in men with ED and diabetes mellitus
Significant improvement on the IIEF and per-attempt intercourse success versus placebo in a hard-to-treat population
Demonstrates efficacy in diabetic erectile dysfunction, where vascular and neuropathic disease blunt response

Quelle ansehen

4Meta-Analyse2014

Avanafil meaningfully improved erectile function versus placebo with a favorable tolerability profile.

Cui, Li, Zong, Yan, Zhang · Asian Journal of Andrology (2014)

Systematic review and meta-analysis pooling randomized placebo-controlled avanafil trials
Avanafil improved IIEF and successful-intercourse rates versus placebo across doses
Tolerability was favorable, with headache and flushing the most common adverse effects

Quelle ansehen

5Systematische Übersicht2017

PDE5-inhibitor administration improved erectile-function recovery after bilateral nerve-sparing radical prostatectomy.

Limoncin, Gravina, Corona, Maggi, Ciocca, Lenzi, Jannini · Andrology (2017)

Systematic review with trial sequential analysis of placebo-controlled RCTs of PDE5 inhibitors (the avanafil class) after radical prostatectomy
PDE5-inhibitor treatment improved erectile-function recovery versus placebo in nerve-sparing surgery
Supports the role of the PDE5-inhibitor class in a major post-surgical ED population

Quelle ansehen

6Open-Label2013

Over 52 weeks, avanafil maintained efficacy with a favorable safety and tolerability profile.

Belkoff, McCullough, Goldstein, Jones, Bowden, DiDonato, Trask, Day · International Journal of Clinical Practice (2013)

52-week open-label extension of two 12-week phase-3 placebo-controlled trials
Sustained improvement in erectile function and successful-intercourse rates over a year of use
Confirms long-term tolerability of a rapidly absorbed, highly selective PDE5 inhibitor

Quelle ansehen

7Präklinisch2014

Avanafil is a potent and highly selective PDE5 inhibitor (a pyrimidine-5-carboxamide derivative) with high selectivity over the other phosphodiesterase isozymes.

Sakamoto, Koga, Hikota, Matsuki, Murakami, Kikkawa, Fujishige, Kotera, Omori, Morimoto, Yamada · Bioorganic & Medicinal Chemistry Letters (2014)

Medicinal-chemistry account of the discovery of avanafil as a pyrimidine-5-carboxamide PDE5 inhibitor
Characterizes high PDE5 potency with high selectivity over PDE6 (retinal) and PDE1
Provides the mechanistic basis for fast onset and a potentially lower visual-side-effect profile than sildenafil

Quelle ansehen

In der Forschungsbibliothek ansehen

Avanafil (Stendra) – Forschung

Überwiegend Mechanismus / Beobachtung

Dual Therapy for Initial Treatment of Adult Patients With Pulmonary Arterial Hypertension: Health Technologies

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.

Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.

Avanafil for male erectile dysfunction: a systematic review and meta-analysis.

Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.

An open-label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction.

The discovery of avanafil for the treatment of erectile dysfunction: a novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor.